Akanda Corp (AKAN)vsHaleon plc (HLN)
AKAN
Akanda Corp
$0.79
-1.45%
HEALTHCARE · Cap: $1.63M
HLN
Haleon plc
$9.74
+0.41%
HEALTHCARE · Cap: $44.83B
Smart Verdict
WallStSmart Research — data-driven comparison
Haleon plc generates 1318237% more annual revenue ($11.03B vs $836,660). HLN leads profitability with a 15.1% profit margin vs -2.7%. AKAN trades at a lower P/E of 0.0x. HLN earns a higher WallStSmart Score of 58/100 (C).
AKAN
Hold36
out of 100
Grade: F
HLN
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+99.9%
Fair Value
$1052.91
Current Price
$0.79
$1052.12 discount
Margin of Safety
+51.3%
Fair Value
$22.93
Current Price
$9.74
$13.19 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Revenue surging 21.9% year-over-year
Earnings expanding 92.0% YoY
Strong operational efficiency at 23.2%
Generating 1.3B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -60.9% — below average capital efficiency
Negative free cash flow — burning cash
Expensive relative to growth rate
0.6% revenue growth
Comparative Analysis Report
WallStSmart ResearchBull Case : AKAN
The strongest argument for AKAN centers on P/E Ratio, Price/Book, Revenue Growth. Revenue growth of 21.9% demonstrates continued momentum.
Bull Case : HLN
The strongest argument for HLN centers on EPS Growth, Operating Margin, Free Cash Flow. Profitability is solid with margins at 15.1% and operating margin at 23.2%.
Bear Case : AKAN
The primary concerns for AKAN are EPS Growth, Market Cap, Return on Equity.
Bear Case : HLN
The primary concerns for HLN are PEG Ratio, Revenue Growth.
Key Dynamics to Monitor
AKAN profiles as a growth stock while HLN is a value play — different risk/reward profiles.
AKAN carries more volatility with a beta of 1.69 — expect wider price swings.
AKAN is growing revenue faster at 21.9% — sustainability is the question.
HLN generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
HLN scores higher overall (58/100 vs 36/100), backed by strong 15.1% margins. AKAN offers better value entry with a 99.9% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Akanda Corp
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Akanda Corporation. The company is headquartered in New Romney, the United Kingdom.
Haleon plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Haleon plc (HLN) is a leading global consumer health company focused on delivering innovative health solutions across critical segments including oral care, pain relief, respiratory health, and dietary supplements. Formed from the spin-off of GlaxoSmithKline, Haleon boasts a strong portfolio of well-established brands, such as Sensodyne, Panadol, and Voltaren, solidifying its presence in the lucrative consumer health market. With a commitment to sustainability and consumer-driven innovation, the company is well-positioned to enhance health outcomes on a global scale while driving growth and delivering shareholder value through strategic investments and product advancements.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?